<DOC>
	<DOCNO>NCT02711423</DOCNO>
	<brief_summary>This two-part study design assess safety , tolerability , PK gantenerumab healthy volunteer . Part I ( dose escalation ) randomly assign participant receive single blind SC dose gantenerumab placebo . Part II ( PK extension ) randomly assign participant receive single open-label SC dose ganenerumab different dose level accord safety assessment Part I .</brief_summary>
	<brief_title>A Single-Dose Study Investigate Safety , Tolerability , Pharmacokinetics ( PK ) Gantenerumab Following Subcutaneous ( SC ) Administration Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy male 18 45 year age , inclusive Body mass index ( BMI ) 20.0 32.0 kilogram per metersquared ( kg/m^2 ) , inclusive History cancer clinically significant disease affect one major organ system Prior administration gantenerumab Clinically significant laboratory test result Clinically relevant history hypersensitivity allergic reaction follow exposure drug , food , environmental agent Known hypersensitivity gantenerumab excipients study drug formulation Abnormal skin condition potentially obscure tattoo , pigmentation , lesion area intend SC injection Familial history earlyonset Alzheimer 's disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>